Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data

Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Friday 25 September →